Market Place
Sourcing Support
Medicenna to Present at 2026 Bloom Burton Investor Conference
14 Apr 2026 //
GLOBENEWSWIRE
Medicenna Announces Changes To Board Composition
13 Feb 2026 //
GLOBENEWSWIRE
Medicenna Therapeutics To Participate In Upcoming Conferences
20 Oct 2025 //
GLOBENEWSWIRE
Medicenna Therapeutics Joins Roth Healthcare Opportunities
01 Oct 2025 //
GLOBENEWSWIRE
Medicenna Announces Results Of Annual Meeting Of Shareholders
25 Sep 2025 //
GLOBENEWSWIRE
Medicenna to Present at HC Wainwright Global Investment Conf
05 Sep 2025 //
GLOBENEWSWIRE
Medicenna Therapeutics Unveils Q1 Fiscal 2026 Results
01 Aug 2025 //
GLOBENEWSWIRE
Medicenna Granted Five Patents for IL-2 and IL-4 Superkines
31 Jul 2025 //
GLOBENEWSWIRE
Medicenna Reports FY25 Financial, Operational Results
26 Jun 2025 //
GLOBENEWSWIRE
Medicenna Shares Anti-PD-1-IL-2 Preclinical Data
30 Apr 2025 //
GLOBENEWSWIRE
Medicenna to Present at 2025 Bloom Burton Healthcare Conference
22 Apr 2025 //
GLOBENEWSWIRE
Medicenna to Present at Jones Healthcare Conference
01 Apr 2025 //
GLOBENEWSWIRE
Medicenna to Update MDNA11 ABILITY-1 Trial at AACR Meeting
26 Mar 2025 //
GLOBENEWSWIRE
Medicenna Reports MDNA11 Expands Cancer-Fighting Cells At AACR-IO
25 Feb 2025 //
GLOBENEWSWIRE
Medicenna Reports Q3 Fiscal 2025 Results & Upcoming Milestones
13 Feb 2025 //
GLOBENEWSWIRE
Medicenna Preclinical Data On MDNA11 For Tumor Shrinking
13 Dec 2024 //
GLOBENEWSWIRE
Medicenna Presents MDNA11 & Bizaxofusp Data at SNO Annual Meeting
25 Nov 2024 //
GLOBENEWSWIRE
Medicenna Reports Q2 FY 2025 Financial Results, Update
15 Nov 2024 //
GLOBENEWSWIRE
Medicenna Announces Presentations at SNO & SABCS 2024
13 Nov 2024 //
GLOBENEWSWIRE
Medicenna Presents Anti-PD1-IL-2 BiSKIT Data at 39th SITC
08 Nov 2024 //
GLOBENEWSWIRE
Medicenna To Present Clinical And Preclinical Data At SITC
04 Oct 2024 //
GLOBENEWSWIRE
Medicenna Announces Results of Annual Meeting of Shareholders
26 Sep 2024 //
GLOBENEWSWIRE
Medicenna Presents Preclinical Results At Conference
09 Sep 2024 //
GLOBENEWSWIRE
Medicenna Announces Presentations At Interleukin-2 Therapy Conference
27 Aug 2024 //
GLOBENEWSWIRE
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
15 Aug 2024 //
GLOBENEWSWIRE
Medicenna Reports Q1 2025 Results And MDNA11 Complete Response
01 Aug 2024 //
GLOBENEWSWIRE
Medicenna Reports Fiscal Year 2024 Financial Results and Operational Highlights
27 Jun 2024 //
GLOBENEWSWIRE
Medicenna Closes CA$20M Investment From RA Capital
30 Apr 2024 //
GLOBENEWSWIRE
Medicenna Announces CA$20M Investment from RA Capital
26 Apr 2024 //
GLOBENEWSWIRE
Medicenna Announces Appointment of New Auditor
12 Jan 2024 //
GLOBENEWSWIRE
Medicenna shifts to Toronto state of mind, Nasdaq listing lapses
27 Oct 2023 //
FIERCE BIOTECH
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
28 Aug 2023 //
GLOBENEWSWIRE
Medicenna Appoints Brent Meadows as Chief Business Officer
14 Aug 2023 //
GLOBENEWSWIRE
Medicenna Commences Monotherapy Dose Expansion in the Phase 1/2 Study
09 Aug 2023 //
GLOBENEWSWIRE
Medicenna Presents at National Brain Tumor Society`s Research Round Table
25 Jul 2023 //
GLOBENEWSWIRE
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
27 Apr 2023 //
GLOBENEWSWIRE
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Conference
18 Apr 2023 //
GLOBENEWSWIRE
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
17 Apr 2023 //
GLOBENEWSWIRE
Medicenna Provides Update from Dose Escalation Portion of Ph 1/2 ABILITY Study
30 Mar 2023 //
GLOBENEWSWIRE
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
15 Mar 2023 //
GLOBENEWSWIRE
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
02 Mar 2023 //
GLOBENEWSWIRE
Medicenna Establishes At-the-Market Sales Facility
17 Feb 2023 //
GLOBENEWSWIRE
Medicenna Reports Third Quarter Fiscal 2023 Financial Results
07 Feb 2023 //
GLOBENEWSWIRE
Medicenna to Present at the 2023 Guggenheim Oncology Conference
31 Jan 2023 //
GLOBENEWSWIRE
Medicenna to Announce Third Quarter Fiscal 2023 Financial Results
26 Jan 2023 //
GLOBENEWSWIRE
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Ph1/2
10 Nov 2022 //
GLOBENEWSWIRE
Medicenna Reports 2Q Fiscal 2023 Financial Results and Operational Highlights
04 Nov 2022 //
GLOBENEWSWIRE
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price
28 Oct 2022 //
GLOBENEWSWIRE
Medicenna to Announce Second Quarter Fiscal 2023 Financial Results
25 Oct 2022 //
GLOBENEWSWIRE
Medicenna Announces Upcoming Presentations at the Society for Immunotherapy
05 Oct 2022 //
GLOBENEWSWIRE
Medicenna Reports Confirmed Partial Response in Pancreatic & Clinical on MDNA11’
28 Sep 2022 //
GLOBENEWSWIRE
Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity
22 Sep 2022 //
GLOBENEWSWIRE
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11
13 Sep 2022 //
GLOBENEWSWIRE
Medicenna Reports First Quarter Fiscal 2023 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Medicenna Announces Closing of Public Offering of Units Raising US$20 M
11 Aug 2022 //
GLOBENEWSWIRE
Medicenna Announces Pricing of US$20 Million Public Offering of Units
09 Aug 2022 //
GLOBENEWSWIRE
Medicenna Announces Launch of a Marketed Underwritten Public Offering of Units
08 Aug 2022 //
GLOBENEWSWIRE
Medicenna to Announce First Quarter Fiscal 2023 Financial Results
05 Aug 2022 //
GLOBENEWSWIRE
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
22 Jun 2022 //
GLOBENEWSWIRE
